Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO Jacqualyn A. Fouse acquired 40,322 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were purchased at an average price of $31.00 per share, with a total value of $1,249,982.00. Following the transaction, the chief executive officer now owns 41,722 shares in the company, valued at approximately $1,293,382. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of AGIO traded up $1.44 during trading hours on Friday, reaching $35.65. The company had a trading volume of 76,990 shares, compared to its average volume of 1,207,647. The firm has a 50 day simple moving average of $33.31 and a 200-day simple moving average of $42.38. The company has a current ratio of 5.30, a quick ratio of 5.24 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -5.91 and a beta of 2.22. Agios Pharmaceuticals Inc has a 12-month low of $28.36 and a 12-month high of $70.70.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.81) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.85) by $0.04. The firm had revenue of $26.02 million for the quarter, compared to analysts’ expectations of $33.13 million. Agios Pharmaceuticals had a negative net margin of 356.42% and a negative return on equity of 70.07%. The firm’s revenue was up 71.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.63) EPS. Sell-side analysts forecast that Agios Pharmaceuticals Inc will post -7.18 earnings per share for the current year.
A number of equities analysts have commented on the stock. Guggenheim upgraded shares of Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Monday, September 23rd. BMO Capital Markets assumed coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 12th. They issued an “outperform” rating and a $45.00 price target for the company. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating and set a $40.00 price target for the company. in a report on Monday, September 16th. Piper Jaffray Companies cut their price target on shares of Agios Pharmaceuticals from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Finally, BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 27th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $62.11.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Further Reading: How to Invest in Growth Stocks
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.